MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

 

 

 


 

Back to products

 

 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

 


Other drug agents

Drug intermediates

Bio-reagents and biochemicals

 


 

 

 

 

 

 

MedKoo product information:

 

LDN-193189

  

LDN193189 is a highly potent small molecule BMP inhibitor with IC50 of 5 and 30 nM for ALK2 and ALK3, respectively. LDN193189 also inhibits BMP type I receptors ALK6 (TGFβ1/BMP signaling) and subsequent SMAD phosphorylation.

   

MedKoo Code#:  501105

Name:  LDN-193189

CAS#:  1062368-24-4

 

Synonym:   LDN-193189

 

IUPAC/Chemical name: 

4-[6-(4-Piperazin-1-yl-phenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline

 

Chemical structure

Theoretical analysis

 

 

 

MedKoo Code#:  501105
Name:  LDN-193189
CAS#:  1062368-24-4

Chemical Formula: C25H22N6

Exact Mass: 406.19059

Molecular Weight: 406.48238

Elemental Analysis: C, 73.87; H, 5.46; N, 20.67

 

 

Availability and price:

This agent is available in stock.

 

To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

 

 

Information about this agent

LDN193189 is a highly potent BMP inhibitor, prevents Smad1, Smad5, and Smad8 phosphorylation through inhibition of BMP type I receptors ALK2 (IC50=5nM) and ALK3 (IC50=30 nM). Its inhibition of ALK4, ALK5, and ALK7 is weak (IC50 >500 nM). As BMP signaling coordinates developmental patterning and has essential physiological roles in mature organisms, LDN-193189 is used to reduce ectopic ossification in a mouse model.

  

 

References

1: Saeed O, Otsuka F, Polavarapu R, Karmali V, Weiss D, Davis T, Rostad B, Pachura K, Adams L, Elliott J, Taylor WR, Narula J, Kolodgie F, Virmani R, Hong CC, Finn AV. Pharmacological Suppression of Hepcidin Increases Macrophage Cholesterol Efflux and Reduces Foam Cell Formation and Atherosclerosis. Arterioscler Thromb Vasc Biol. 2011 Nov 17. [Epub ahead of print] PubMed PMID: 22095982.

2: Kudo TA, Kanetaka H, Mizuno K, Ryu Y, Miyamoto Y, Nunome S, Zhang Y, Kano M, Shimizu Y, Hayashi H. Dorsomorphin stimulates neurite outgrowth in PC12 cells via activation of a protein kinase A-dependent MEK-ERK1/2 signaling pathway. Genes Cells. 2011 Nov;16(11):1121-32. doi: 10.1111/j.1365-2443.2011.01556.x. Epub 2011 Oct 12. PubMed PMID: 21988724.

3: Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFß and BMP pathways. Cell Signal. 2011 Nov;23(11):1831-42. Epub 2011 Jun 29. PubMed PMID: 21740966.

4: Cross EE, Thomason RT, Martinez M, Hopkins CR, Hong CC, Bader DM. Application of small organic molecules reveals cooperative TGFβ and BMP regulation of mesothelial cell behaviors. ACS Chem Biol. 2011 Sep 16;6(9):952-61. Epub 2011 Jul 20. PubMed PMID: 21740033; PubMed Central PMCID: PMC3177035.

5: Theurl I, Schroll A, Sonnweber T, Nairz M, Theurl M, Willenbacher W, Eller K, Wolf D, Seifert M, Sun CC, Babitt JL, Hong CC, Menhall T, Gearing P, Lin HY, Weiss G. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood. 2011 Nov 3;118(18):4977-84. Epub 2011 Jul 5. PubMed PMID: 21730356; PubMed Central PMCID: PMC3208302.

6: Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res. 2011 Aug 1;71(15):5194-203. Epub 2011 Jun 13. PubMed PMID: 21670081; PubMed Central PMCID: PMC3148283.

7: Yonezawa T, Lee JW, Hibino A, Asai M, Hojo H, Cha BY, Teruya T, Nagai K, Chung UI, Yagasaki K, Woo JT. Harmine promotes osteoblast differentiation through bone morphogenetic protein signaling. Biochem Biophys Res Commun. 2011 Jun 3;409(2):260-5. Epub 2011 May 6. PubMed PMID: 21570953.

8: Steinbicker AU, Sachidanandan C, Vonner AJ, Yusuf RZ, Deng DY, Lai CS, Rauwerdink KM, Winn JC, Saez B, Cook CM, Szekely BA, Roy CN, Seehra JS, Cuny GD, Scadden DT, Peterson RT, Bloch KD, Yu PB. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011 May 5;117(18):4915-23. Epub 2011 Mar 10. PubMed PMID: 21393479; PubMed Central PMCID: PMC3100698.

9: Wang L, Trebicka E, Fu Y, Ellenbogen S, Hong CC, Babitt JL, Lin HY, Cherayil BJ. The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis. 2012 Jan;18(1):112-9. doi: 10.1002/ibd.21675. Epub 2011 Feb 23. PubMed PMID: 21351217; PubMed Central PMCID: PMC3139830.

10: Shi S, Hoogaars WM, de Gorter DJ, van Heiningen SH, Lin HY, Hong CC, Kemaladewi DU, Aartsma-Rus A, ten Dijke P, 't Hoen PA. BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. Neurobiol Dis. 2011 Feb;41(2):353-60. Epub 2010 Oct 16. PubMed PMID: 20940052.

11: Katagiri T, Kamizono J, Nakashima Y, Kitoh H, Susami T, Haga N. [Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva]. Clin Calcium. 2010 Oct;20(10):1510-7. Review. Japanese. PubMed PMID: 20890033.

12: Cannon JE, Upton PD, Smith JC, Morrell NW. Intersegmental vessel formation in zebrafish: requirement for VEGF but not BMP signalling revealed by selective and non-selective BMP antagonists. Br J Pharmacol. 2010 Sep;161(1):140-9. PubMed PMID: 20718746; PubMed Central PMCID: PMC2962823.

13: Boergermann JH, Kopf J, Yu PB, Knaus P. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem Cell Biol. 2010 Nov;42(11):1802-7. Epub 2010 Aug 5. PubMed PMID: 20691279.

14: Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, McManus PM, Katagiri T, Sachidanandan C, Kamiya N, Fukuda T, Mishina Y, Peterson RT, Bloch KD. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008 Dec;14(12):1363-9. Epub 2008 Nov 30. Erratum in: Nat Med. 2009 Jan;15(1):117. PubMed PMID: 19029982; PubMed Central PMCID: PMC2846458.

15: Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4388-92. Epub 2008 Jun 27. PubMed PMID: 18621530; PubMed Central PMCID: PMC2570262.


 

Contact MedKoo:

Email: sales@medkoo.com

 

 

(Keyword; CAS#; MedKoo code#)

 

 

 

 

 

 

 

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

© MedKoo Biosciences. All Rights Reserved